Vicuron (NASDAQ:MICU)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Vicuron Charts. Click Here for more Vicuron Charts.](/p.php?pid=staticchart&s=N%5EMICU&p=8&t=15)
Spector, Roseman & Kodroff, P.C. Announces the Filing of a Class
Action Suit Against Vicuron Pharmaceuticals
PHILADELPHIA, July 7 /PRNewswire/ -- The law firm of Spector, Roseman &
Kodroff, P.C. announces that a class action lawsuit was commenced in the United
States District Court for the Eastern District of Pennsylvania, on behalf of
purchasers of the securities of Vicuron Pharmaceuticals, Inc. ("Vicuron" or the
"Company") (NASDAQ:MICU) between March 17, 2003 through May 24, 2004, inclusive
(the "Class Period").
The Complaint alleges that defendants violated the federal securities laws by
issuing materially false and misleading statements contained in press releases
and filings with the Securities and Exchange Commission during the Class
Period. Specifically, the Complaint alleges that during the Class Period,
defendants artificially inflated the price of Vicuron stock by concealing
critical material information regarding the details of both the safety and
efficacy of anidulafungin. Defendants concealed key adverse information
regarding the development and commercialization of anidulafungin, raising
serious concerns for the very approval of the drug for the treatment of
esophageal candidiasis and other selected indications.
If you purchased Vicuron securities during the Class Period, you may, no later
than August 16, 2004, move to be appointed as a Lead Plaintiff in this class
action. A Lead Plaintiff is a representative, chosen by the Court, that acts
on behalf of other class members in directing the litigation. The Private
Securities Litigation Reform Act of 1995 directs Courts to assume that the
class member(s) with the "largest financial interest" in the outcome of the
case will best serve the class in this capacity. Courts have discretion in
determining which class member(s) have the "largest financial interest," and
have appointed Lead Plaintiffs with substantial losses in both absolute terms
and as a percentage of their net worth.
If you have sustained substantial losses in Vicuron securities during the Class
Period, please contact Spector, Roseman & Kodroff, P.C. at for a more thorough
explanation of the Lead Plaintiff selection process. If you have relatively
small losses, your ability to participate in any recovery will be protected by
the Lead Plaintiff(s), and you need take no affirmative steps at this time.
If you wish to join this action, please visit
http://www.srk-law.com/dbjoinaclassaction.asp. If you wish to discuss this
action or have any questions concerning this notice or your rights or
interests, please contact plaintiff's counsel Robert M. Roseman toll-free at
888-844-5862 or via e-mail at . For more detailed information about the firm
please visit its website at http://www.srk-law.com/.
Spector, Roseman & Kodroff, P.C., located in Philadelphia, Pennsylvania,
concentrates its practice in complex litigation including actions dealing with
securities laws, antitrust, contract and commercial claims. The firm is active
in major litigation pending in federal and state courts throughout the United
States. The firm's reputation for excellence has been recognized on repeated
occasions by courts which have appointed the firm as lead counsel in numerous
major class actions involving violations of the federal securities laws and the
federal antitrust laws, and consumer fraud. As a result of the efforts of the
firm, and its members, hundreds of millions of dollars have been recovered on
behalf of thousands of defrauded shareholders and companies.
DATASOURCE: Spector, Roseman & Kodroff, P.C.
CONTACT: Robert M. Roseman of Spector, Roseman & Kodroff, P.C.,
+1-888-844-5862
Web site: http://www.srk-law.com/
http://www.srk-law.com/dbjoinaclassaction.asp